Entries by CAPTIS

Merck to buy biopharmaceutical firm ArQule for $2.7bn

ArQule is involved in the research and development of targeted therapeutics for the treatment of cancers and certain rare diseases. The company’s clinical-stage pipeline consists of four drug The post Merck to buy biopharmaceutical firm ArQule for $2.7bn appeared first on Pharmaceutical Business review.

Calquence significantly prolonged time patients lived without disease progression or death in previously untreated CLL

The Independent Review Committee (IRC)-assessed results were presented at the 2019 American Society of Hematology Annual Meeting and Exhibition in Orlando, US. At a median follow-up of 28.3 The post Calquence significantly prolonged time patients lived without disease progression or death in previously untreated CLL appeared first on Pharmaceutical Business review.

Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments

Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches. The post Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments appeared first on Pharmaceutical Business review.